Development of an effective vaccine against the hepatitis C virus (HCV) has long been
defined as a difficult challenge due to the considerable variability of this RNA virus and the …

There is no vaccine for HCV and the only available treatment, IFNα alone or in combination
with ribavirin, has proven efficacious in less than 50% of patients. Given that approximately …

Despite major advances in the understanding and treatment of hepatitis C, a preventive
vaccine remains elusive. The marked genetic diversity and multiple mechanisms of …

The hepatitis C virus was discovered 15 years ago as the agent responsible for most cases
of transfusion-associated hepatitis non-A, non-B. At present, 180 million people worldwide …

Hepatitis C virus (HCV) is a blood-borne pathogen which has chronically infected about 130–
210 million people worldwide. Current standard-of-care (SoC) therapy is an inadequate and …

Hepatitis C virus (HCV) infects more than 170 million people globally and is a leading cause
of liver cirrhosis, transplantation and hepatocellular carcinoma. Current gold-standard …

Prophylactic hepatitis C virus (HCV) vaccine trials with human volunteers are pending.
There is an important need for immunological end points which correlate with vaccine …

Given the global disease burden and public health impact of hepatitis C, the development of
an effective vaccine is of paramount importance. However, many challenging obstacles …

Natural cross-protective immunity is induced after spontaneous clearance of primary
hepatitis C virus (HCV) infection. Although this suggests that effective prophylactic vaccines …

Prevention of hepatitis C virus (HCV) infection by vaccination has been a priority since
discovery of the virus and the need has not diminished over the past 25 years. Infection rates …